Hussman Strategic Advisors Inc. Makes New Investment in Emergent BioSolutions Inc. (NYSE:EBS)

Hussman Strategic Advisors Inc. bought a new position in shares of Emergent BioSolutions Inc. (NYSE:EBS) during the 4th quarter, Holdings Channel reports. The fund bought 21,000 shares of the biopharmaceutical company’s stock, valued at approximately $201,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. New York State Common Retirement Fund raised its stake in shares of Emergent BioSolutions by 41.7% during the 4th quarter. New York State Common Retirement Fund now owns 306,286 shares of the biopharmaceutical company’s stock worth $2,928,000 after buying an additional 90,113 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of Emergent BioSolutions during the 4th quarter worth $1,831,000. Assenagon Asset Management S.A. raised its stake in shares of Emergent BioSolutions by 3.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 766,537 shares of the biopharmaceutical company’s stock worth $7,328,000 after buying an additional 24,985 shares during the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in shares of Emergent BioSolutions during the 3rd quarter worth $295,000. Finally, Barclays PLC raised its stake in shares of Emergent BioSolutions by 361.6% during the 3rd quarter. Barclays PLC now owns 39,308 shares of the biopharmaceutical company’s stock worth $329,000 after buying an additional 30,792 shares during the last quarter. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent BioSolutions Stock Down 1.6 %

EBS opened at $7.85 on Friday. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. The stock has a market capitalization of $425.04 million, a price-to-earnings ratio of -1.91 and a beta of 1.62. The business has a 50-day moving average of $9.67 and a two-hundred day moving average of $9.09. Emergent BioSolutions Inc. has a 12 month low of $1.66 and a 12 month high of $15.10.

Analyst Ratings Changes

Several research analysts have recently issued reports on EBS shares. StockNews.com raised Emergent BioSolutions from a “hold” rating to a “buy” rating in a research note on Monday. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Emergent BioSolutions in a research note on Tuesday, January 21st. Finally, Benchmark boosted their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 7th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.